Literature DB >> 20698047

Early ileocolonoscopy with biopsy for the evaluation of persistent post-transplantation diarrhea.

Giorgos Bamias1, John Boletis, Theodoros Argyropoulos, Chrysanthi Skalioti, Spyros I Siakavellas, Ioanna Delladetsima, Irene Zouboulis-Vafiadis, George L Daikos, Spiros D Ladas.   

Abstract

AIM: To investigate the significance of ileocolonoscopy with histology in the evaluation of post-transplantation persistent diarrhea (PD).
METHODS: We retrospectively reviewed all records of renal transplant patients with PD, over a 3-year period. All patients were referred for ileocolonoscopy with biopsy, following a negative initial diagnostic work up. Clinical and epidemiological data were compared between cases with infectious or drug-induced diarrhea.
RESULTS: We identified 30 episodes of PD in 23 renal transplant patients (1-3 cases per patient). There were 16 male patients and the mean age at the time of PD was 51.4 years. The average time from transplantation to a PD episode was 62.3 +/- 53.2 mo (range 1-199 mo). Ileocolonoscopy detected mucosal abnormalities in 19 cases, whereas the intestinal mucosa appeared normal in 11 cases. Histological examination achieved a specific diagnosis in 19/30 cases (63.3%). In nine out of 11 cases (82%) with normal endoscopic appearance of the mucosa, histological examination of blinded biopsies provided a specific diagnosis. The etiology of PD was infectious in 11 cases (36.6%), drug-related in 10 (33.3%), of other causes in three (10%), and of unknown origin in six cases (20%). Infectious diarrhea occurred in significantly longer intervals from transplantation compared to drug-related PD (85.5 +/- 47.6 mo vs 40.5 +/- 44.8 mo, P < 0.05). Accordingly, PD due to drug-toxicity was rarely seen after the first year post-transplantation. Clinical improvement followed therapeutic intervention in 90% of cases. Modification of immunosuppressive regimen was avoided in 57% of patients.
CONCLUSION: Early ileocolonoscopy with biopsies from both affected and normal mucosa is an important adjunctive tool for the etiological diagnosis of PD in renal transplant patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20698047      PMCID: PMC2921096          DOI: 10.3748/wjg.v16.i30.3834

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  26 in total

1.  Diarrhoea following renal transplantation.

Authors:  Mehmet Riza Altiparmak; Sinan Trablus; Omer Nuri Pamuk; Süheyla Apaydin; Muzaffer Sariyar; Recep Oztürk; Rezzan Ataman; Kamil Serdengeçti; Ekrem Erek
Journal:  Clin Transplant       Date:  2002-06       Impact factor: 2.863

2.  Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group.

Authors:  J Miller; R Mendez; J D Pirsch; S C Jensik
Journal:  Transplantation       Date:  2000-03-15       Impact factor: 4.939

Review 3.  Gastrointestinal infectious disease complications following transplantation and their differentiation from immunosuppressant-induced gastrointestinal toxicities.

Authors:  R H Rubin
Journal:  Clin Transplant       Date:  2001       Impact factor: 2.863

4.  Villous atrophy induced by mycophenolate mofetil in renal-transplant patients.

Authors:  Nassim Kamar; Patrick Faure; Emmanuel Dupuis; Olivier Cointault; Karine Joseph-Hein; Dominique Durand; Jacques Moreau; Lionel Rostaing
Journal:  Transpl Int       Date:  2004-08-21       Impact factor: 3.782

5.  Incidence and risk factors for diarrhea following kidney transplantation and association with graft loss and mortality.

Authors:  Suphamai Bunnapradist; Luca Neri; Wendy Wong; Krista L Lentine; Thomas E Burroughs; Brett W Pinsky; Steven K Takemoto; Mark A Schnitzler
Journal:  Am J Kidney Dis       Date:  2008-03       Impact factor: 8.860

6.  Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation.

Authors:  Greg A Knoll; Ian MacDonald; Asmat Khan; Carl Van Walraven
Journal:  J Am Soc Nephrol       Date:  2003-09       Impact factor: 10.121

7.  The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation.

Authors:  Ronald P Pelletier; Baris Akin; Mitchell L Henry; Ginny L Bumgardner; Elmahdi A Elkhammas; Amer Rajab; Ronald M Ferguson
Journal:  Clin Transplant       Date:  2003-06       Impact factor: 2.863

8.  Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial.

Authors:  R S Gaston; B Kaplan; T Shah; D Cibrik; L M Shaw; M Angelis; S Mulgaonkar; H-U Meier-Kriesche; D Patel; R D Bloom
Journal:  Am J Transplant       Date:  2009-05-20       Impact factor: 8.086

9.  Colonoscopy is a useful diagnostic tool for transplant recipients with lower abdominal symptoms.

Authors:  M Korkmaz; G Gür; U Yilmaz; H Karakayali; S Boyacioğlu; M Haberal
Journal:  Transplant Proc       Date:  2004 Jan-Feb       Impact factor: 1.066

10.  Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host disease-like pattern.

Authors:  John C Papadimitriou; Charles B Cangro; Alexander Lustberg; Amr Khaled; Joseph Nogueira; Ann Wiland; Emilio Ramos; David K Klassen; Cinthia B Drachenberg
Journal:  Int J Surg Pathol       Date:  2003-10       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.